Kevin Balthaser - Mar 1, 2025 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Financial Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Mar 1, 2025
Transactions value $
-$1,447
Form type
4
Date filed
3/4/2025, 04:15 PM
Previous filing
Feb 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +1.1K +1.22% 91K Mar 1, 2025 Direct F1
transaction ACRS Common Stock Options Exercise +2.38K +2.61% 93.3K Mar 1, 2025 Direct F1
transaction ACRS Common Stock Tax liability -$1.45K -727 -0.78% $1.99 92.6K Mar 1, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -1.1K -100% $0.00 0 Mar 1, 2025 Common Stock 1.1K Direct F1, F3
transaction ACRS Restricted Stock Units Options Exercise $0 -2.38K -50% $0.00 2.38K Mar 1, 2025 Common Stock 2.38K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F4 The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.